Calidi Biotherapeutics 3Q 2026: EPS ($1.47) — 10-Q Summary
Calidi Biotherapeutics reported no product sales in Q3 2026. Net loss narrowed to $3.65M from $10.82M YoY, with EPS at ($1.47). R&D costs rose, while G&A expenses fell. Other income increased due to a German research refund and fair-value gains. The company plans to cut 67% of headcount, expecting $3M in annual savings.
How this was made
The 30-second read
Why it matters
The filing shows a significant loss reduction and a major headcount cut, suggesting near‑term cost discipline but still reflects a high‑risk, loss‑making biotech.
Market read
First‑time earnings disclosure for CLDI with improved loss metrics and restructuring; modest trading relevance for biotech micro‑caps.
What to watch
The $0.6 M German research allowance refund is a one‑time item and may not repeat, tempering the perceived improvement.
Background
Calidi Biotherapeutics (CLDI) is a clinical‑stage biotech focused on oncolytic viruses. The 10‑Q covers Q3 2026 with no product sales.
Ticker impact
Calidi Biotherapeutics filed its 10‑Q reporting a narrowed net loss and a $0.6 M research allowance refund, plus a restructuring plan to cut headcount by ~67%.
modest upside as the market prices in the loss narrowing and restructuring savings
Loss per share improved dramatically year‑over‑year and the announced headcount reduction suggests future expense discipline, which traders may view as a catalyst for a short‑term rally.
Market effects
Biotech sector may see slight positive sentiment as a loss‑narrowing result from a small‑cap company highlights cost‑control trends.
US small‑cap biotech investors could adjust exposure based on the restructuring news.
Limited to niche biotech investors; no broader market impact.
Counterpoint
The loss remains sizable and no product revenue was generated; the restructuring could signal deeper operational challenges.
Key entities
- companyCalidi Biotherapeutics
US‑listed biotech (ticker CLDI) reporting Q3 2026 results.
